Careers
Contact Us
Navigate Adaptimmune Limited
Home
Our Company
Overview
Board of Directors
Executive Team
Partners
Scientific Advisory Board
Perspectives
Pipeline
Overview
ADP-A2M10 (MAGE-A10)
ADP-A2M4 (MAGE-A4)
ADP-A2AFP (AFP)
Technology
Overview
The Immune System
Our Engineered T-Cell Therapies
Our Technology Platform
Manufacturing
Intellectual Property
Publications
Patients & Families
Overview
Our Clinical Trials
Taking Part in our Clinical Trials
Clinical Trial FAQ
Cancer Information
Cancer Immunotherapy Month
Videos
News & Events
News
Scientific Conferences
Investor Conferences
Investors
Click here to see our Second Quarter 2019 Financial Results and Business Update
Click Here
Adaptimmune announces start of SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
Read More
You can find new videos about our SPEAR T-cells
Learn More
Explore stories from our colleagues and external experts on our science and how we're working to improve patient lives by transforming cancer treatment
Click Here
Focusing on the needs of our patients
Learn More
Enhancing the Affinity of T-cell to Fight Cancer
Learn More
Latest News •
View all
August 1, 2019
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
August 1, 2019
New Executive Team Announced at Adaptimmune
July 29, 2019
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
Adaptimmune on Linkedin
Adaptimmune on Twitter
Tweets by Adaptimmune
Clinical Trials
Our Pipeline
Manufacturing
Partnerships
Perspectives
